A Phase III, Randomized, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Trial Profile

A Phase III, Randomized, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Iron isomaltoside 1000 (Primary) ; Ferrous sulfate
  • Indications Cancer; Chemotherapy-induced anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms PROFOUND
  • Sponsors Pharmacosmos
  • Most Recent Events

    • 01 Mar 2016 Primary endpoint has been met, (Change in Hb Concentration), according to the results published.
    • 01 Mar 2016 Results published in the Pharmacotherapy.
    • 26 Jul 2014 According to the European Clinical Trials Database record, status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top